Talphera

Talphera EBITDA Growth YoY

The Year-over-Year EBITDA Growth of Talphera (TLPH) as of Nov 6, 2026 is -101.00 %. In the previous year, Year-over-Year EBITDA Growth was -3.16 % — a change of 3,098.90% (lower).

EBITDA Growth YoY

-101.00 %

YoY

3,098.90%

Last updated:

Year-over-Year EBITDA Growth of Talphera is 2025 -101.00 % . Year-over-Year EBITDA Growth of Talphera was 2024 -3.16 % . It decreases by 3,098.90% lower compared to the previous year.

The Talphera EBITDA Growth YoY history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Growth YoY
Date
EBITDA Growth YoY
Jan 1, 2018
7.64 USD
Jan 1, 2019
-51.72 USD
Jan 1, 2020
24.43 USD
Jan 1, 2021
55.77 USD
Jan 1, 2022
-12.34 USD
Jan 1, 2023
6,910.20 USD
Jan 1, 2024
-3.16 USD
Jan 1, 2025
-101.00 USD
The Talphera EBITDA Growth YoY history
YEAREBITDA Growth YoYYoY
-101.00 %+3,098.90%
-3.16 %-100.05%
6,910.20 %-56,086.18%
-12.34 %-122.13%
55.77 %+128.31%
24.43 %-147.23%
-51.72 %-777.03%
7.64 %-136.30%
-21.04 %-68.34%
-66.46 %-235.61%
49.01 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Talphera Stock analysis

What does Talphera do? Talphera Inc develops and commercializes therapies for medically supervised settings, focusing on nafamostat-based products. The company's Niyad targets regional anticoagulants for dialysis circuits in acute kidney injury and chronic kidney disease patients. LTX-608 is an intravenous formulation for potential treatment of viral infections, ARDS, DIC, and acute pancreatitis. Pre-filled syringes Fedsyra and PFS-02 are also under development. The firm sells these products to hospitals, dialysis centers, and medical facilities requiring specialized therapies in controlled environments. Niyad is designed for use during continuous renal replacement therapy and hemodialysis procedures, primarily targeting healthcare providers in hospital settings and dialysis centers. LTX-608 aims to address viral and inflammatory conditions, with potential buyers including hospitals treating respiratory and coagulation disorders. The pre-filled syringes Fedsyra and PFS-02 serve as delivery systems for these therapies, appealing to medical institutions needing efficient administration solutions. The company's revenue streams come from the sale of Niyad, LTX-608, Fedsyra, and PFS-02 to healthcare providers. Hospitals and dialysis centers are key buyers for Niyad, while LTX-608 targets hospitals managing viral outbreaks and severe inflammatory conditions. Fedsyra and PFS-02 are sold as complementary products to support the delivery of nafamostat therapies, with demand driven by the need for specialized medical treatments in supervised care settings. Talphera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Talphera stock

Year-over-Year EBITDA Growth of Talphera is -101.00 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBITDA Growth Talphera since 2006 – with annual values, charts, and detailed analysis.

EBITDA growth measures the percentage change in EBITDA compared to the prior year. It shows changes in operating cash earnings before capital structure effects.

To evaluate Year-over-Year EBITDA Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBITDA Growth.

Year-over-Year EBITDA Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBITDA Growth's Talphera historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Talphera

All Key Metrics — Talphera